Skip to main content

Asia-Pacific capabilities

Our hybrid model supports your therapeutic’s commercialization goals within the APAC region, with the flexibility to go global.

Your global laboratory services partner in advancing drug development in Asia

The Asia-Pacific (APAC) region is rapidly becoming a hotspot for global clinical trials. In our 2025 Future of the Central Lab report, we highlighted a growing trend among biopharma leaders to expand their clinical trials globally, increase in the number of trials being conducted in APAC countries such as China, Japan, South Korea and India. As this shift offers many benefits to biopharma companies - ranging from reduced study costs, access to large and diverse patient populations and faster recruitment timelines - Labcorp’s extensive experience and established presence in APAC offers comprehensive support for your drug development so you can bring innovative therapies to patients faster.

  • Comprehensive drug development capabilities from nonclinical to clinical stages across the Asia-Pacific region

  • Reliable and combinable high-quality data that meets global regulatory compliance needs

  • Rapid turnaround time that keeps your drug development milestone targets on track

bml

We’re connected across APAC to meet your needs.

We’re here to support you at any stage of your drug development journey. Whether you are a nimble biotech or a large organization, we know how to support your mission and get you the solutions you need—at the right time and place.

Key facilities in APAC

test1

Nonclinical facility
Location: Shanghai, China
Started: 2010
Facility space: >8,300 m2
Key services: In vivo pharmacology, ADME, In vivo and In vitro DMPK, non-GLP and GLP toxicology studies

Immunology and immunotoxicology laboratory
Location: Shanghai, China
Started: 2019
Facility space: ~200 m2
Key services: Flow cytometry analysis, cell-based assays, immunoassays, molecular analysis

lab researcher working in the lab

Singapore
Started: 2000
Facility space: >6,300 m2
Key services: Safety Testing, Special Chemistry, Immunology, Flow cytometry, Targeted Cell Isolation, Microbiology, Anatomical Pathology and Histology, Genomics, Pre-analytical and Specimen Management Services

China
Location: Shanghai
Started: 2007
Facility space: >7,100 m2
Key services: Safety Testing, Special Chemistry, Immunology, Flow cytometry, Targeted Cell Isolation, Microbiology, Anatomical Pathology and Histology, Genomics, Pre-analytical and Specimen Management Services

Japan
Location: Kawagoe
Started: 2010
Facility space: >4,000 m2
Key services: Safety Testing, Special Chemistry, Immunology, Flow cytometry, Targeted Cell Isolation, Microbiology, Anatomical Pathology and Histology, Genomics, Pre-analytical and Specimen Management Services

Up close image of a pipette inside of a petri dish

Singapore
Started: 2021
Facility space: >1,000 m2
Key services: Method Development, Method Validation, and Sample Analysis for both preclinical and clinical studies. Offering a broad series of analytical services spanning small molecule, large molecule and clinical biomarkers.

China
Location: Shanghai
Started: 2008
Facility space: >6,400 m2
Key services: Method Development, Method Validation, and Sample Analysis for both preclinical and clinical studies. Offering a broad series of analytical services spanning small molecule, large molecule and clinical biomarkers.

kit fullfillment facility

China
Location: Suzhou
Started: 2023
Facility space: >4,900 m2
Key services: Provide the kits for clinical trials in China

A proven track record in accelerating drug development

Since establishing our first facilities in 1998, Labcorp APAC has expanded to 15 countries and regions, with a dedicated team of more than 3,000 employees. Our decades of experience providing global laboratory services means you’ll benefit from clearer insights, robust data and deep regulatory knowledge to overcome challenges throughout your drug development journey.

Together, we can drive your drug development forward and make a real impact on people’s lives.

By the numbers

1998 Entered the APAC market
3 Countries with state-of-the-art facilities (China, Japan, Singapore)
3 countries with central laboratories (China, Japan, Singapore)
1 country with nonclinical facility (China)
3,000+ employees
14 countries/regions where we support drug development
2 countries with bioanalysis laboratories (China, Singapore)
1 country with kit fulfillment facility (China)

APAC Trending Topics

SINGAPORE CAPABILITIES OVERVIEW

JAPAN CAPABILITIES OVERVIEW

CHINA CAPABILITIES OVERVIEW

Article

Labcorp and BML announce expansion of clinical laboratory testing capabilities in Japan

Labcorp (NYSE: LH), a leading global life sciences company, broke ground on a the expansion project of its CB Trial Laboratory in a ceremony held at the construction site near the BML Research Institute and General Laboratory in Kawagoe City on April 28, 2023.

Learn more
bml
Close up portrait of Asian businesswoman, beside male senior coworker, smiling and laughing, respect, admiration

Articles

Navigating complexities in ADC development with specialized global laboratory support and scientific expertise

A global biopharmaceutical client developing a pipeline of complex antibody-drug conjugates (ADCs) needed a reliable global lab partner. Given the range of cancer applications and the challenges involved in optimizing ADC components and characterizing these multifaceted biopharmaceuticals, the client sought comprehensive lab services and scientific expertise to support their clinical trials through commercialization.

Learn more

Resources

Let's start a conversation